AR113906A1 - Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple - Google Patents

Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple

Info

Publication number
AR113906A1
AR113906A1 ARP180103432A ARP180103432A AR113906A1 AR 113906 A1 AR113906 A1 AR 113906A1 AR P180103432 A ARP180103432 A AR P180103432A AR P180103432 A ARP180103432 A AR P180103432A AR 113906 A1 AR113906 A1 AR 113906A1
Authority
AR
Argentina
Prior art keywords
cladribine
multiple sclerosis
regime
progressive forms
treat progressive
Prior art date
Application number
ARP180103432A
Other languages
English (en)
Inventor
Fernando Dangond
Dotzauer Matthias Dr
Original Assignee
Merck Patent Ges Mit Beschraenkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64457023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR113906(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Ges Mit Beschraenkter Haftung filed Critical Merck Patent Ges Mit Beschraenkter Haftung
Publication of AR113906A1 publication Critical patent/AR113906A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Cladribina para usar en el tratamiento oral de pacientes que padecen formas progresivas de esclerosis múltiple, caracterizada porque dicha cladribina se ha de administrar en forma oral a cada paciente a una dosis fija por paciente, por peso corporal y por año de tratamiento, donde dicha dosis fija se selecciona del rango de 1,5 mg/kg a 4,0 mg/kg.
ARP180103432A 2017-11-24 2018-11-23 Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple AR113906A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762590442P 2017-11-24 2017-11-24

Publications (1)

Publication Number Publication Date
AR113906A1 true AR113906A1 (es) 2020-06-24

Family

ID=64457023

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103432A AR113906A1 (es) 2017-11-24 2018-11-23 Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple

Country Status (15)

Country Link
US (3) US10849919B2 (es)
EP (1) EP3713582A1 (es)
JP (1) JP7495345B2 (es)
KR (1) KR20200090824A (es)
CN (1) CN111356460A (es)
AR (1) AR113906A1 (es)
AU (1) AU2018372007A1 (es)
BR (1) BR112020010282A2 (es)
CA (1) CA3083328A1 (es)
EA (1) EA202091253A1 (es)
IL (1) IL274777A (es)
MX (2) MX2020005266A (es)
SG (1) SG11202004772RA (es)
TW (1) TW201936199A (es)
WO (1) WO2019101960A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230066402A (ko) * 2020-09-10 2023-05-15 메르크 파텐트 게엠베하 자가면역 장애의 치료를 위한 신규 치료 용법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
HUT77928A (hu) 1994-12-22 1998-11-30 Ortho Pharmaceutical Corporation Oldható 2-klór-2'-dezoxi-adenozint tartalmazó gyógyászati készítmények
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
WO2004028462A2 (en) 2002-09-25 2004-04-08 Brigham Young University, Technology Transfer Office Method for the preparation of 2-halo-2'-deoxyadenosine compounds from 2'-deoxyguanosine
EP1608344B1 (en) 2003-03-28 2010-08-04 Ares Trading S.A. Oral formulations of cladribine
MXPA05010330A (es) 2003-03-28 2006-05-31 Ivax Corp Formulaciones de cladribina para el mejor suministro oral y a traves de la mucosa.
EP2263678B1 (en) * 2004-12-22 2014-06-11 Merck Serono SA Cladribine regimen for treating early secondary progressive Multiple Sclerosis
PL2026832T3 (pl) * 2006-05-24 2012-08-31 Merck Serono Sa Skojarzony reżim interferonu beta i kladrybiny do leczenia stwardnienia rozsianego
US10000516B2 (en) * 2015-08-26 2018-06-19 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders

Also Published As

Publication number Publication date
EA202091253A1 (ru) 2020-09-29
EP3713582A1 (en) 2020-09-30
US20230021880A1 (en) 2023-01-26
US20190167707A1 (en) 2019-06-06
KR20200090824A (ko) 2020-07-29
TW201936199A (zh) 2019-09-16
MX2020005266A (es) 2020-09-18
MX2023007405A (es) 2023-06-29
WO2019101960A1 (en) 2019-05-31
US20210169912A1 (en) 2021-06-10
US10849919B2 (en) 2020-12-01
SG11202004772RA (en) 2020-06-29
CA3083328A1 (en) 2019-05-31
AU2018372007A1 (en) 2020-07-09
BR112020010282A2 (pt) 2020-11-17
IL274777A (en) 2020-07-30
JP7495345B2 (ja) 2024-06-04
JP2021504363A (ja) 2021-02-15
CN111356460A (zh) 2020-06-30

Similar Documents

Publication Publication Date Title
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
CO2018004776A2 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
CL2018001677A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
JP2017506624A5 (es)
MX2021002321A (es) Nuevos metodos.
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
MX2021002322A (es) Nuevos metodos.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
AR100784A1 (es) Micropartículas multicomponentes para usar en una formulación inhalable, proceso para preparar, formulación farmacéutica, inhalador
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
AR113906A1 (es) Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
AR102308A1 (es) Composición farmacéutica para usar en el tratamiento o prevención de deficiencias de vitaminas y minerales en pacientes sometidos a cirugía de bypass gástrico
CL2021001389A1 (es) Formulaciones en cápsula
MX2018015208A (es) Andrografolido para tratar formas progresivas de esclerosis multiple.
UY32670A (es) Utilizacion de alfa -1-antitripisina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica
CO2019003808A2 (es) Composición farmacéutica que comprende antagonista receptor de mineralocorticoides y uso de la misma
CO2018009543A2 (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma
AR112229A1 (es) Composición farmacéutica para usar en el tratamiento o la prevención de deficiencias de vitaminas y deficiencias de minerales en pacientes que fueron sometidos a una cirugía de banda gástrica
BR112018009476A2 (pt) regime de dosagem de plasminogênio para cicatrização de ferimentos
MX2021015338A (es) Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.
AR105087A1 (es) Métodos para el tratamiento de mujeres con trastorno de deseo sexual hipoactivo (hsdd) con el tratamiento de combinación bupropión y trazodona